RNXT

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• RenovoRx advances its TAMP platform into borderline resectable pancreatic cancer with the first patient enrolled in the investigator-initiated PRISM-TAMP trialOct 7, 2026
• RenovoRx announces a peer-reviewed publication highlighting the TAMP platform's potential to improve chemotherapy delivery in locally advanced pancreatic cancerOct 1, 2026
• RenovoRx received a U.S. patent allowance covering RenovoCath, its advanced dual-occlusion catheter for targeted drug delivery in cancer treatmentAug 20, 2026
• RenovoRx achieved full enrollment in the Phase 3 TIGeR-PaC trial for locally advanced pancreatic cancerAug 11, 2026
• RenovoRx announced the first commercial clinical use of RenovoCath in a sarcoma patient, expanding the device to additional solid tumorsAug 6, 2026